Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Encora Therapeutics | 2022 | Grant | Undisclosed | Boston |
| ReviveMed | 2022 | Seed | Undisclosed | Cambridge |
| TracFlo | 2021 | Pre-Seed | $1.0M | New York |
| Coral Genomics | 2021 | Grant | $1.7M | San Francisco |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 101 | Encora Therapeutics | Grant | Undisclosed | Boston, United States |
| 102 | ReviveMed | Seed | Undisclosed | Cambridge, United States |
| 103 | TracFlo | Pre-Seed | $1.0M | New York, United States |
| 104 | Coral Genomics | Grant | $1.7M | San Francisco, United States |
Encora helps people with neurodegenerative movement disorders regain independence and control in their lives.
ReviveMed is a precision-medicine platform that leverages the data from small molecules or metabolites.
TracFlo: Streamline project finances. Input, track, and approve changes in one platform, preventing disputes and managing scope creep.
Coral develops new clinical tests to help providers streamline prior authorization and select the effective medication.
SBXi has invested in 104 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
SBXi's top investment sectors include Health Care, Biotechnology, Information Technology, Medical, Medical Device. The firm invests across 15 different industry categories.
Among tracked funding rounds, Coral Genomics received $1.7M in a Grant round. SBXi's total known invested capital is $171.4M.
SBXi's average investment size is $2.3M across its portfolio of 104 companies.
Recent SBXi portfolio additions include Encora Therapeutics, ReviveMed, TracFlo, Coral Genomics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors